Dovitinib Companion Diagnostic Shows Results in RCC

The drug response predictor companion diagnostic for dovinitib (DRP-Dovitinib) demonstrates potential to identify patients with advanced renal cell carcinoma (RCC) who are most likely to respond positively from its treatment, according to a study in PLOS.

In the sensitive group, median progression-free survival (PFS) was 3.8 months, and in the sorafenib arm, median PFS was 3.6 months (hazard ratio [HR], 0.71; 95% CI, 0.51-1.01). The median overall survival (OS) in the sensitive group was 15.0 months. In the sorafenib arm, median OS was 11.2 months (HR, 0.69; 95% CI, 0.48-0.99).

Observed clinical benefit increased with a higher drug response predictor (DRP) score. The DRP-Dovitinib was also unable to identify patients that benefited from sorafenib, which supports that the it is drug-specific and not prognostic.

The manufacturer of the drug, also reported that the device delivers a 2-4-fold higher response rate when combined with dovitinib compared with use without a prior DRP screen.

Read the full story on targetedonc.com HERE